Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.24 – $0.66
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $215.0K | $5.5M | $0 | $30.8M | $145.7M | $173.9M | $158.2M | $276.3M |
| Cost of revenue | $0 | $0 | $0 | $21.8M | $86.9M | $85.6M | $80.9M | $157.4M |
| Gross profit | $215.0K | $5.5M | $0 | $9.0M | $58.8M | $88.2M | $77.3M | $118.9M |
| Gross margin | 100.0% | 100.0% | — | 29.4% | 40.3% | 50.7% | 48.9% | 43.0% |
| R&D | $76.0M | $136.1M | $225.2M | $414.4M | $407.8M | $413.6M | $283.0M | $141.6M |
| Operating income | −$112.2M | −$203.5M | −$440.8M | −$759.1M | −$855.9M | −$789.6M | −$459.3M | −$241.7M |
| EBITDA | −$116.0M | −$194.4M | −$454.0M | −$738.7M | −$752.3M | −$655.7M | −$488.7M | −$162.0M |
| Net income | −$272.6M | −$633.3M | −$1.66B | −$702.3M | −$846.1M | −$768.0M | −$590.6M | −$541.0M |
| Net margin | -126798.1% | -11549.5% | — | -2280.5% | -580.7% | -441.7% | -373.3% | -195.8% |
| EPS (diluted) | -4.19 | -2.20 | -12.61 | -1.76 | -2.06 | -1.87 | -1.43 | -1.33 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $321M | $-0.79 | $-0.79–$-0.79 | 1 |
| 2027 | $832M | $-0.50 | $-0.50–$-0.50 | 1 |
Forward consensus · source: Financial Modeling Prep
JW CAYMAN THERAPEUTICS CO
No one on the platform currently holds JWCTF.
No tracked institution reports a position in JWCTF as of their last filing.
No one on the platform has traded JWCTF yet.
| $155M |
| — |
| MLLCFMolecular Partners AG | $3.60 | +0.00% | $135M | — |
| NDTPNDT Pharmaceuticals Inc. | $0.35 | -26.16% | $56M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.3× sales vs its 0.8× historical median P/S.
Fair value ≈ $0.60 · price $0.24 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.